K08670903

Kromasil^® Eternity^™ C18 HPLC Column

5 μm particle size, pore size 100 Å, L × I.D. 250 mm × 4.6 mm

• Synonym(e): Kromasil C18
• UNSPSC-Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Eigenschaften

• Agentur: suitable for USP L1
• Produktlinie: Kromasil^®
• Hersteller/Markenname: Kromasil^® ET-5-C18-4.6X250
• Verfügbarkeit: available only in USA, Canada and Puerto Rico
• Kennzeichnungsgrad: 14% Carbon loading
• Methode(n): HPLC: suitable
• L × ID: 250 mm × 4.6 mm
• Oberflächenbereich: 330 m²/g
• Aktive Matrixgruppe: C18 (octadecyl) phase
• Partikelgröße: 5 μm
• Porengröße: 100 Å
• pH-Bereich: 1-12
• Anwendung(en): food and beverages
• Trenntechnik: reversed phase

Beschreibung

Anwendung

• Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma.: This study developed and validated an HPLC-MS/MS method for determining clopidogrel in human plasma. The Kromasil^® Eternity C18 HPLC column was employed to achieve the separation. This method was shown to be efficient, precise, and suitable for pharmacokinetic studies (Liu et al., 2016).


• Development and validation of stability-indicating assay method by UPLC for a fixed dose combination of atorvastatin and ezetimibe.: The study focused on developing a stability-indicating assay method for atorvastatin and ezetimibe using UPLC. The Kromasil^® Eternity C18 HPLC column was critical in achieving the required resolution and sensitivity, demonstrating its role in stability studies of pharmaceutical combinations (Goel et al., 2013).

Rechtliche Hinweise

Eternity is a trademark of EKA Chemicals AB

Kromasil is a registered trademark of EKA Chemicals AB